Sign in Subscribe
United States. Securities and Exchange Commission

Vertex Pharmaceuticals Inc. Files SEC Form 4 for Director-Officer Ownership

Strategic Insights

— 1 min read

Vertex Pharmaceuticals Inc., a leading developer of innovative medicines for the treatment of serious diseases, recently filed a Form 4 with the U.S. Securities and Exchange Commission (SEC) on March 6, 2015. The filing reports a director-officer's ownership and transactions of equity securities. As a publicly-traded company, Vertex Pharmaceuticals Inc. is required to submit regular reports to the SEC regarding ownership and transactions of its equity securities.

Key Takeaways:

  • The SEC filing (Form 4) was submitted by Vertex Pharmaceuticals Inc. on March 6, 2015, with the SEC file number 0001209191-15-023545.
  • The filing reports the director-officer's ownership and transactions of equity securities, as required by the Securities Exchange Act of 1934.
  • The Form 4 filing contains information on the reporting person's relationship to Vertex Pharmaceuticals Inc. and on purchases and sales of equity securities.
  • The contact information for Vertex Pharmaceuticals Inc. is 50 NORTHERN AVENUE, BOSTON MA 02210, with a phone number of 6173416393.

Statistics:

  • The SIC code for Vertex Pharmaceuticals Inc. is 2834, indicating Pharmaceutical Preparations as the company's primary business classification.
  • The SEC filing reports one document filed with Form 4.
  • The contact information for the company is accurately recorded in the SEC filing.

Sources:

  • NewsRx LLC, "Vertex Pharmaceuticals Inc. Files SEC Form 4 for Director-Officer Ownership," March 6, 2015.
  • Securities and Exchange Commission (SEC), "Form 4: Insider Trading - SEC Filing," accessed March 6, 2015.
  • Vertex Pharmaceuticals Inc., "SEC Form 4 Filing Details," accessed March 6, 2015.

Read more